Background: Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in patients with a range of cancers. Although limited and discordant data suggest that BB may increase overall survival (OS) in localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC.
Introduction
Stress is usually considered among the numerous factors involved in the complex process of cancer carcinogenesis. However, how stressors or stress response impact the natural history of this disease is unknown. During stress response, the activation of sympathetic nervous system (SNS) and the hypothalamic pituitary adrenal (HPA) axes ultimately lead to the release of epinephrine and norepinephrine. These two 'survival' hormones activate trans-membrane and nuclear receptors that through downstream activation promote cell survival, proliferation and motility [1] . These responses are observed in normal and malignant cells exposed to these hormones in the setting of in vitro models [2] . Both the SNS and HPA converge to potentiate tumor growth [1] . In pre-clinical animal models in which chronic stress is applied, the increase in stress intensity and serum catecholamine levels are both related to tumor growth [3] . This induction of tumor growth mediated by stress hormones seems to be blocked by betaadrenergic antagonists [3] . Beta-blockers (BB) have been found to inhibit tumor invasiveness and metastatic spread in vitro [2, 4] .
Retrospective studies have reported improved cancer control endpoints in patients treated for ovarian and breast cancer receiving BB as treatment for concomitant conditions [5] [6] [7] . However, methodological limitations do not allow firm conclusions as to the anti-cancer activity of BB. In a previous communication we have shown a marginal improvement in overall survival (OS) in patients developing treatment emergent hypertension (TEH) in the ROSE/TRIO-012 study [8] . Other studies have shown similar results [9] . We hypothesized that the improvement in cancer outcomes seen in patients developing TEH, in our and other studies, could be related to the concomitant use of BB rather than to the development of TEH itself. Consequently, we conducted a retrospective analysis of the relationship between BB usage and PFS in women with advanced BC enrolled in the ROSE/TRIO-012 trial.
Patients and methods
The ROSE/TRIO-012 study was a multicenter, double-blind phase III trial evaluating first-line docetaxel with or without ramucirumab in patients with HER2-negative advanced breast cancer. The study randomized 1144 patients (in a 2:1 ratio) and failed to show improvement in the primary endpoint of progression-free survival (PFS) with the addition of ramucirumab [10] . We retrospectively identified in the Intent-To-Treat (ITT) population those receiving concomitant treatment with any dose of BB during the study (either during the active treatment phase and/or within 30 days prior to randomization). Among these patients we identified two cohorts, those on BB prior to randomization ('baseline' cohort) and those who began BB after randomization ('after baseline' cohort). Patients receiving BB prior to and after randomization were considered in the 'baseline' cohort.
We compared PFS, OS, overall response rate (ORR), Duration of response (DoR) and clinical benefit rate (CBR) according to BB intake (received versus did not receive) and BB treatment timing (received after baseline versus did not receive) in the ITT population. Additionally, in the subgroup of patients with hormone receptor positive BC and in those with triple negative BC (TNBC), we compared PFS and OS according to BB intake. Lastly, considering the potential prognostic value of TEH in cancer patients treated with anti-VEGF therapies, we compared the PFS of patients who developed TEH with those who did not develop this event, irrespective of BB intake. TEH was defined as hypertension with onset date before day 42 after study treatment start, the first studymandated tumor response assessment.
PFS and OS were estimated using the Kaplan-Meier method. The PFS and OS of the different treatment cohorts were compared using the LogRank test. Cox proportional models were used to estimate the hazard ratio (HR) for PFS and OS based on BB intake. Results are expressed in HR and 95% CIs. A univariate test for association of survival time was performed. The variables evaluated in the univariate analyses include BB intake, development of TEH, hormone receptor status and treatment arm. Variables that were associated in the univariate analysis were included in a multivariate analysis. When more than one variable was associated with the survival time, a test for interaction was conducted in order to identify if the result could be primarily explained by one of the tested variables. ORR and CBR in the different cohorts were compared using the Fisher's Exact Test. Results are expressed in odds ratio (OR) and 95% CIs. Statistical tests were performed using a two-sided 0.05 significance level. Statistical analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC).
To provide an independent validation of the test-set findings in TRIO-012, a confirmatory analysis was performed on data from the BCIRG-005 study, using identical methods. BCIRG-005 was a phase III trial that randomized 3298 women with HER2 non-amplified operable breast cancer to adjuvant doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC-> T) every 3 weeks for four cycles or to docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles [11] .
Results
A total of 153 patients (13% of the ITT population) received BB during TRIO-012 trial; 71% of them (N ¼ 108) were randomized to the ramucirumab arm. The median duration of follow-up was 25.1 months. The main patients' characteristics are reported in supplementary Table S1 , available at Annals of Oncology online. Patient and treatment characteristics were balanced between patients taking and not taking BB with the exception of age, Eastern Cooperative Oncology Group performance status and menopausal status.
Sixty two percent of patients (N ¼ 96) had BB at baseline and 38% (N ¼ 57) began BB after study entry. The most frequently used BB were bisoprolol (N ¼ 59), metoprolol (N ¼ 48), atenolol (N ¼ 28) and propranolol (N ¼ 13). The median duration of treatment with BB was 147 days and the most frequent indications for BB treatment were hypertension (70%), coronary heart disease (12%), arrhythmia (10%) and heart failure (1%).
Median PFS in patients treated with BB was 10.3 months compared to 8.3 months in patients who did not receive them (HR 0.81; 95% CI 0.66-0.99; P ¼ 0.038) ( Figure 1B ). When analyzed according to timing of BB treatment, the median PFS in the after baseline cohort was 15.5 months versus 8.3 months in patients that did not receive BB (HR 0.57; 95% CI 0.41-0.78; P < 0.001) ( Figure 1C ).
No PFS benefit was observed in patients with hormone receptor positive disease that received BB versus those who did not receive them (10.1 versus 9.8 months; HR 0.93; 95% CI 0.74-1.16; P ¼ 0.509) ( Figure 2A ). In contrast, PFS was more than doubled in TNBC patients, when comparing those who received BB with those who did not (13.0 versus 5.2 months; HR 0.52; 95% CI 0.34-0.80; P ¼ 0.002) ( Figure 2B ).
The median PFS for patients with TEH was 9.8 months compared to 8.4 months in patients not developing TEH, irrespective of BB intake (P ¼ 0.313, HR 0.89 and 95% CI 0.71-1.11) ( Figure 1A) .
In the univariate analysis, treatment arm and hormone receptor status were associated with PFS (P ¼ 0.023 and 0.001, respectively) (supplementary Table S2 , available at Annals of Oncology online). Of note, TEH was not associated with PFS (P ¼ 0.311). In the multivariate analysis, all the variables associated in the univariate analysis were retained (hormone receptor P < 0.001; treatment arm P ¼ 0.017). No interaction was identified between treatment arm and BB use (P ¼ 0.637) (supplementary Table S3 , available at Annals of Oncology online).
There was no significant difference in OS in patients who received BB versus those who did not, regardless of timing of BB use and breast cancer subtype (all BB patients: 27.7 months versus 29.7 months; HR 1.05; 95% CI 0.85-1.29 P ¼ 0.646; TNBC with BB: 19.5 months versus 19.6 months; HR 0.87; 95% CI 0.58-1.31 P ¼ 0.504). Similarly, no differences were observed in ORR (39.9% versus 42.9%; OR 0.88 95% CI 0.61-1.27; P ¼ 0.539), and CBR (86.3% versus 84.6%; OR 0.63 95% CI 0.50-1.44; P ¼ 0.631). Mean DoR did not differ significantly in those taking versus not taking BB, either in the ITT population (10 versus 12 months; P ¼ 0.112) or the TNBC patients (8.6 versus 13.9 months; P ¼ 0.066).
In the analysis of the BCIRG-005 data (validation dataset), we identified a trend to improved relapse-free survival in subjects exposed to BB (N ¼ 205) compared to those that did not receive BB (N ¼ 3093; HR 0.75; 95% CI 0.54-1.02; P ¼ 0.073) (supplementary Figure S1A , available at Annals of Oncology online). Even though not statistically significant, a pronounced improvement in relapse-free survival was seen in women with TNBC (N ¼ 35; HR 0.69; 95% CI 0.35-1.34; P ¼ 0.269) (supplementary Figure  S1B , available at Annals of Oncology online). Similarly to TRIO-012 study, no OS improvements were seen in the entire patient population (HR 0.97; 95% CI 0.70-1.32; P ¼ 0.844) or the TNBC subgroup (HR 0.73; 95% CI 0.35-1.48; P ¼ 0.384).
Discussion
In this exploratory analysis BB intake was associated with a significant improvement in PFS in patients with HER2 negative advanced BC. Previous studies have suggested a possible anticancer effect of BB [5] [6] [7] 12] . However, this signal is inconsistent and mainly comes from retrospective cohort studies with limited number of patients and varying endpoints. Powe et al. [5] report a single institution experience that early BC patients receiving BB as concomitant medication while on adjuvant therapy experienced a longer disease-free interval, reduced risk for metastasis development, and reduced breast cancer mortality. Watkins et al. [6] conducted a multicenter review of an ovarian cancer patient cohort receiving chemotherapy mainly for loco-regional and advanced disease, in which BB intake was associated with improved OS but no results were reported on PFS. MelhemBertrandt et al. [7] reported a significant improvement in relapse-free survival in early BC patients receiving BB while on and after neoadjuvant therapy; no benefit in OS was observed.
In addition to these individual studies, two meta-analyses have been conducted to estimate the impact of BB on cancer endpoints. Raimondi et al. [12] performed a meta-analysis that included more than 46 000 patients from 11 BC studies and found a significant improvement in BC specific survival for patients treated with BB. Weberpals et al. [13] also found evidence of improvement in overall and cancer-specific survival with the use of these drugs in their systematic review and meta-analysis that included more than 88 000 patients with ovarian, colorectal, lung, prostate and breast tumors from 30 studies. However, this improvement was not confirmed when the studies deemed to be prone to immortal time bias were excluded.
Other studies have explored the influence of BB in cancer prevention and cancer specific mortality, with inconsistent results [14, 15] . In addition, the anti-cancer effects of other classes of anti-hypertensive drugs have been examined. Although there are some reports of the potential anti-tumor effect of angiotensinconverting enzyme (ACE) inhibitors, the evidence is less consistent and more limited than that for BB [16] .
Our study represents the largest reported cohort of BC patients exploring the impact of BB on cancer outcomes. The ROSE/ TRIO-012 population is well-characterized and treated with current 'state of the art' care, and these data derive from a prospectively collected phase III randomized registration trial. Because the experimental ramucirumab therapy did not significantly impacted on patients' outcomes, the ROSE/TRIO-012 population provides a good opportunity to evaluate the potential anticancer effect of drugs given to treat comorbidities. To our knowledge, this is the first BB study restricted to patients with advanced cancer. We found BB use to be associated with a significant improvements in PFS, which is a more specific endpoint than OS when investigating a new intervention in cancer patients; while other studies have shown an improvement in OS, the distinction between an anticancer effect of BB or reduction in cardiovascular events cannot be made [6, 12] . Additionally, unlike OS, the results observed in PFS are minimally influenced by the immortal time bias.
The ORR was similar and although not statistically significant, the mean duration of response was longer in patients receiving The Kaplan-Meier analysis shows no significant difference in PFS in patients with hormone receptor positive disease that received versus those that did not receive BB. (B) A significant improvement in PFS has been observed in TNBC that received BB compared to those who did not receive them. BB, beta-blocker; PFS, progression-free survival; TNBC, triple negative breast cancer.
BB compared to non-BB patients, and was doubled in the TNBC subgroup. This suggests that BB could have a cytostatic effect. All patients who participated in the ROSE/TRIO-012 study received docetaxel and therefore the benefit of the BB may indicate a synergistic interaction with chemotherapy. This may occur by blocking certain collateral effects of chemotherapy that can induce tumor growth such as release of cytokines or inflammation [17] . Chemotherapy can also induce a stress response, triggering adaptive responses by the SNS and the HPA adrenal axes [18] . BB may block part of this response by the inhibition of the effects of stress hormones. The role of glucocorticoid administration could not be evaluated in this study since dexamethasone was mandated for all patients as pre-medication.
It has been reported that the development of hypertension under anti-VEGF therapy is predictive of its anti-cancer benefit [19] . Based on this, we have considered TEH as a potentially explanatory variable in univariate and multivariate analyses. We did not find a benefit in PFS in patients that developed TEH in the entire ITT population. Similarly, no significant effect of TEH has been found in the regression analyses in patients receiving BB. Based on this, we postulate that it may not be the development of hypertension per se, but its treatment with commonly used anti-hypertensive agents with potential anti-cancer effect, explaining the improvement in PFS in patients treated with BB.
Although the PFS benefit of BB intake was evident in the entire ITT population, the largest benefit was observed in patients with TNBC and in those that began BB after randomization. Other authors have similarly shown a particular benefit in the TNBC subtype receiving BB [7] . It has been described that stress may play an important role in resistance to chemotherapy in TNBC animal models [20] and that psychological stress can induce gene expression changes in mammary adipose tissue that ultimately lead to secretion of pro-inflammatory cytokines and growth factors [21] . Inflammation is well known characteristic of some TNBC subtypes and has been postulated to play a key role in its pathogenesis. Blockade of the effector stress response may be a mechanistic explanation of the BB effect we observed in TNBC.
We note that the association between BB and improved PFS was seen in the whole ITT population, and that the effect is independent of treatment arm (as confirmed by a negative test for interaction). However, based on the common observation that previous exposure to an anti-cancer agent is related to a decrease in its efficacy we analyzed whether the timing of BB treatment influenced the PFS results. We observed that patients not previously exposed to BB were the ones deriving the majority of the benefit in comparison to patients who were already receiving them before randomization. The differential benefit based on previous exposure to BB has already been suggested in a previous study. Zhong et al. [22] showed that patients who received BB after cancer diagnosis had a reduction in cancer-specific mortality compared to non BB users, while those who received BB prior to cancer diagnosis had no benefit. Prolonged treatment with BB is known to be related to an increase in the density of betaadrenergic receptors in the membrane of non-transformed cardiac cells (up-regulation). While these phenomena has not been previously described in malignant cells, our results suggest that previous exposure of malignant cells to BB may render them less sensitive to this therapeutic approach. This could be also explained by the use of alternative proliferation pathways. Analysis of the expression of adrenergic receptors in the archived tumor samples collected in the ROSE/TRIO-012 could be valuable to further test the mechanistic hypothesis that receptor upregulation may have a role in BB sensitivity in BC cells.
In order to validate the results observed in TRIO-012, a similar analysis was conducted using BCRIG-005 data. Notably, we found consistent results in this validation dataset in patients with HER2 negative disease, reinforcing our results and suggesting that the activity of BBs may not be limited to advanced disease. Even though the results in patients with TNBC are nonstatistically significant, they are consistent toward improved outcomes in this BC subtype. Considering these and the previous results available, a meaningful effect of these drugs should not be ruled out, as a consequence of small sample size in both studies.
Our study has several limitations. This is a retrospective analysis and is subject to bias. While the total number of patients who received BB in our study is the largest cohort of advanced BC published so far, the exploratory analyses based on BC subtype and treatment timing were necessarily on smaller subsets. We have not explored the effect of other concomitant medications with known potential anti-cancer effect including ACE inhibitors, metformin and non-steroidal agents. Neither we examined interactions between BB and other anti-hypertensive drugs due to small sample size. Finally, is important to note that since patients with a longer PFS interval had more chances to receive a BB after baseline, censoring of progressive disease events may have biased more favorable results in this subgroup.
To conclude, we have shown that advanced BC patients receiving concomitant BB in the ROSE/TRIO-012 study had significantly better PFS compared to non-exposed patients, and this effect was largely confined to those patients with TNBC and those that began treatment with BB after enrollment in the study. These findings were replicated in an independent validation dataset in patients with early HER2 negative breast cancer receiving standard adjuvant chemotherapy. These results support investigating blockade of beta-adrenergic receptors as a strategy to treat BC. This could be especially valuable in TNBC patients where chemotherapy remains the only treatment option. Because BBs are inexpensive and well-established agents with an excellent safety profile, prospective controlled studies are feasible.
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